{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:38:10Z","timestamp":1791999490160,"version":"4.4.0"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Inflammatory processes are involved in the pathophysiology of both Alzheimer\u2019s disease (AD) and multiple sclerosis (MS) but their exact contribution to disease progression remains to be deciphered. Biomarkers are needed to define pathophysiological processes of these disorders, who may increasingly co-exist in the elderly generations of the future, due to the rising prevalence in both and ameliorated treatment options with improved life expectancy in MS. The purpose of this review was to provide a systematic overview of inflammatory biomarkers, as measured in the cerebrospinal fluid (CSF), that are associated with clinical disease progression. International peer-reviewed literature was screened using the PubMed and Web of Science databases. Disease progression had to be measured using clinically validated tests representing baseline functional and\/or cognitive status, the evolution of such clinical scores over time and\/or the transitioning from one disease stage to a more severe stage. The quality of included studies was systematically evaluated using a set of questions for clinical, neurochemical and statistical characteristics of the study. A total of 84 papers were included (twenty-five for AD and 59 for MS). Elevated CSF levels of chitinase-3-like protein 1 (YKL-40) were associated with disease progression in both AD and MS. Osteopontin and monocyte chemoattractant protein-1 were more specifically related to disease progression in AD, whereas the same was true for interleukin-1 beta, tumor necrosis factor alpha, C-X-C motif ligand 13, glial fibrillary acidic protein and IgG oligoclonal bands in MS. We observed a broad heterogeneity of studies with varying cohort characterization, non-disclosure of quality measures for neurochemical analyses and a lack of adequate longitudinal designs. Most of the retrieved biomarkers are related to innate immune system activity, which seems to be an important mediator of clinical disease progression in AD and MS. Overall study quality was limited and we have framed some recommendations for future biomarker research in this field.<\/jats:p><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42021264741.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1162340","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T19:38:03Z","timestamp":1689277083000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer\u2019s disease and multiple sclerosis: a systematic review"],"prefix":"10.3389","volume":"14","author":[{"given":"Joke","family":"Temmerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Engelborghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bjerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"D\u2019haeseleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur J Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70259-X","article-title":"Cognitive impairment in multiple sclerosis","volume":"7","author":"Chiaravalloti","year":"2008","journal-title":"Lancet Neurology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.045872","article-title":"Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis","volume":"76","author":"Deloire","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2019.03.016","article-title":"Relevance of the interplay between amyloid and tau for cognitive impairment in early alzheimer\u2019s disease","volume":"79","author":"Timmers","year":"2019","journal-title":"Neurobiol Aging"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-011-0607-8","article-title":"Mechanisms of neurodegeneration shared between multiple sclerosis and alzheimer\u2019s disease","volume":"118","author":"Lassmann","year":"2011","journal-title":"J Neural Transm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019","volume":"7","author":"Nichols","year":"2022","journal-title":"Lancet Public Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.10.109","article-title":"Coexistence of multiple sclerosis and alzheimer\u2019s disease: a review","volume":"27","author":"Luczynski","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201489","article-title":"Inflammatory diseases, inflammatory biomarkers, and Alzheimer disease: an observational analysis and mendelian randomization","volume":"100","author":"Huang","year":"2023","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"103351","DOI":"10.1016\/j.msard.2021.103351","article-title":"Diagnosis of alzheimer\u2019s disease and related dementia among people with multiple sclerosis: Large cohort study, USA","volume":"57","author":"Mahmoudi","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2016-207809","article-title":"Associations between specific autoimmune diseases and subsequent dementia: retrospective record-linkage cohort study, UK","volume":"71","author":"Goldacre","year":"2017","journal-title":"J Epidemiol Community Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-019-1674-2","article-title":"Molecular biomarkers in multiple sclerosis","volume":"16","author":"Ziemssen","year":"2019","journal-title":"J Neuroinflamm"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170327","article-title":"The cerebrospinal fluid A\u03b21-42\/A\u03b21-40 ratio improves concordance with amyloid-PET for diagnosing alzheimer\u2019s disease in a clinical setting","volume":"60","author":"Niemantsverdriet","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of alzheimer\u2019s disease: recommendations from the national institute on aging-alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30346-X","article-title":"PET imaging of neuroinflammation in neurological disorders","volume":"19","author":"Kreisl","year":"2020","journal-title":"Lancet Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2022.10.020","article-title":"Microglia states and nomenclature: a field at its crossroads","volume":"110","author":"Paolicelli","year":"2022","journal-title":"Neuron"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimer\u2019s Dementia: Trans Res Clin Interventions"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-022-02580-1","article-title":"Pathogenesis, therapeutic strategies and biomarker development based on \u201comics\u201d analysis related to microglia in alzheimer\u2019s disease","volume":"19","author":"Gao","year":"2022","journal-title":"J Neuroinflamm"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00337","article-title":"Friend, foe or both? immune activity in alzheimer\u2019s disease","volume":"11","author":"Frost","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/bs.pmbts.2019.10.002","article-title":"Neuroimmune interactions in alzheimer\u2019s disease\u2013new frontier with old challenges","volume":"168","author":"Prokop","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012109","article-title":"Astrocyte biomarkers in Alzheimer disease: a systematic review and meta-analysis","volume":"96","author":"Bellaver","year":"2021","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03892-7","article-title":"A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis","volume":"597","author":"Absinta","year":"2021","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww258","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0035-2","article-title":"Progressive multiple sclerosis: from pathophysiology to therapeutic strategies","volume":"18","author":"Faissner","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa275","article-title":"Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis","volume":"143","author":"Sucksdorff","year":"2020","journal-title":"Brain"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7188","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","author":"Patsopoulos","year":"2019","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-022-05534-y","article-title":"Microglia regulate central nervous system myelin growth and integrity","volume":"17","author":"McNamara","year":"2022","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323087","article-title":"Prognostication and contemporary management of clinically isolated syndrome","volume":"92","author":"Allen","year":"2021","journal-title":"Neurol Neurosurg Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00519-3","article-title":"The multiple sclerosis prodrome","volume":"17","author":"Makhani","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309690","article-title":"Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome","volume":"87","author":"Disanto","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6649","article-title":"Radiologically isolated syndrome: a review for neuroradiologists","volume":"41","author":"Hosseiny","year":"2020","journal-title":"Am J Neuroradiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00927-z","article-title":"The alzheimer\u2019s disease drug development landscape","volume":"13","author":"van Bokhoven","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13215","article-title":"Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis","volume":"289","author":"Piehl","year":"2021","journal-title":"J Intern Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-012-2007-7","article-title":"Chapter 2: medical tests guidance (2) developing the topic and structuring systematic reviews of medical tests: utility of PICOTS, analytic frameworks, decision trees, and other frameworks","volume":"27","author":"Samson","year":"2012","journal-title":"J Gen Intern Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000118082","article-title":"Clinical dementia rating","volume":"145","author":"Berg","year":"1984","journal-title":"Br J Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for alzheimer\u2019s disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-79948-3_532","article-title":"Dementia rating scale-2","volume-title":"Encyclopedia of clinical neuropsychology","author":"Griffiths","year":"2011"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.11.1621","article-title":"The FAB: a frontal assessment battery at bedside","volume":"55","author":"Dubois","year":"2000","journal-title":"Neurology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.39.9.1159","article-title":"The consortium to establish a registry for alzheimer\u2019s disease (CERAD). part i. clinical and neuropsychological assesment of alzheimer\u2019s disease","volume":"39","author":"Morris","year":"1989","journal-title":"Neurology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1879437","article-title":"The effect of osteopontin on microglia","volume":"2017","author":"Yu","year":"2017","journal-title":"BioMed Res Int"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-1309","article-title":"Osteopontin is increased in the cerebrospinal fluid of patients with alzheimer\u2019s disease and its levels correlate with cognitive decline","volume":"19","author":"Comi","year":"2010","journal-title":"J Alzheimer\u2019s Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/615745","article-title":"Elevated osteopontin levels in mild cognitive impairment and alzheimer\u2019s disease","volume":"2013","author":"Sun","year":"2013","journal-title":"Mediators Inflamm"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple sclerosis severity score","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517690618","article-title":"Age related multiple sclerosis severity score: disability ranked by age","volume":"23","author":"Manouchehrinia","year":"2017","journal-title":"Mult Scler"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1982.tb03091.x","article-title":"Prognosis of multiple sclerosis. results from an epidemiological area in Germany","volume":"65","author":"Poser","year":"1982","journal-title":"Acta Neurol Scand"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00598","article-title":"New multiple sclerosis disease severity scale predicts future accumulation of disability","volume":"8","author":"Tackenberg","year":"2017","journal-title":"Front Neurol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.107052","article-title":"Early prediction of the long term evolution of multiple sclerosis: the Bayesian risk estimate for multiple sclerosis (BREMS) score","volume":"78","author":"Bergamaschi","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch Neurol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia","volume":"140","author":"Hughes","year":"1982","journal-title":"Br J Psychiatry"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2008.00188.x","article-title":"Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in alzheimer\u2019s disease","volume":"19","author":"Sokolova","year":"2009","journal-title":"Brain Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51109","article-title":"Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of alzheimer\u2019s disease","volume":"7","author":"Pillai","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030525","article-title":"CCL2 is associated with a faster rate of cognitive decline during early stages of alzheimer\u2019s disease","volume":"7","author":"Westin","year":"2012","journal-title":"PloS One"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1177\/135245859900500409","article-title":"The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment","volume":"5","author":"Fischer","year":"1999","journal-title":"Multiple Sclerosis J"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1177\/135245859500100306","article-title":"The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study","volume":"1","author":"Bever","year":"1995","journal-title":"Multiple Sclerosis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1177\/1352458506070750","article-title":"Screening for cognitive impairment in multiple sclerosis using the symbol digit modalities test","volume":"13","author":"Parmenter","year":"2007","journal-title":"Mult Scler"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro-2019-0100","article-title":"YKL-40 and neuron-specific enolase in neurodegeneration and neuroinflammation","volume":"31","author":"Dichev","year":"2020","journal-title":"Rev Neurosci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1732-9","article-title":"The IL-1\u03b2 phenomena in neuroinflammatory diseases","volume":"125","author":"Mendiola","year":"2018","journal-title":"J Neural Transm"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2016.07.148","article-title":"Neuronal pentraxin 2 predicts medial temporal atrophy and memory decline across the alzheimer\u2019s disease spectrum","volume":"58","author":"Swanson","year":"2016","journal-title":"Brain Behav Immun"},{"key":"B70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","article-title":"Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor alzheimer\u2019s disease in a memory clinic cohort","volume":"7","author":"Kester","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/NIB-150101","article-title":"Targeting CXCL13 during neuroinflammation","volume":"6","author":"Huber","year":"2015","journal-title":"Adv Neuroimmune Biol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20928","article-title":"Innate immunity and neuroinflammation in the CNS: the role of microglia in toll-like receptor-mediated neuronal injury","volume":"58","author":"Lehnardt","year":"2010","journal-title":"Glia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7379.41","article-title":"Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative","volume":"326","author":"Bossuyt","year":"2003","journal-title":"BMJ"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/brain\/aww34","article-title":"An early and late peak in microglial activation in alzheimer\u2019s disease trajectory","volume":"140","author":"Fan","year":"2017","journal-title":"Brain"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1326-8-20","article-title":"Fluid biomarkers in alzheimer\u2019s disease - current concepts","volume":"8","author":"Ros\u00e9n","year":"2013","journal-title":"Mol Neurodegener"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-013-0161-z","article-title":"Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases","volume":"36","author":"Bose","year":"2013","journal-title":"Arch Pharm Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of alzheimer\u2019s fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci11020215","article-title":"Cerebrospinal fluid biomarkers of alzheimer\u2019s disease: current evidence and future perspectives","volume":"11","author":"McGrowder","year":"2021","journal-title":"Brain Sci"},{"key":"B80","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/biomedicines10040840","article-title":"The role of osteopontin in microglia biology: current concepts and future perspectives","volume":"10","author":"Rosmus","year":"2022","journal-title":"Biomedicines"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-022-02047-1","article-title":"Role of chemokines in the development and progression of alzheimer\u2019s disease","volume":"72","author":"Wojcieszak","year":"2022","journal-title":"J Mol Neurosci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-023-01257-z","article-title":"Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of alzheimer\u2019s disease","volume":"26","author":"De Schepper","year":"2023","journal-title":"Nat Neurosci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s13311-021-01179-3","article-title":"Microglia in alzheimer\u2019s disease: a key player in the transition between homeostasis and pathogenesis","volume":"19","author":"Mcfarland","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/CON.0000000000001136","article-title":"Epidemiology and pathophysiology of multiple sclerosis","volume":"28","author":"Goldman","year":"2022","journal-title":"CONTINUUM Lifelong Learn Neurol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1212\/NXI.0000000000001139","article-title":"Slowly expanding lesions predict 9-year multiple sclerosis disease progression","volume":"9","author":"Preziosa","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200144","article-title":"Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis","volume":"98","author":"Calvi","year":"2022","journal-title":"Neurology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221080667","article-title":"The expansion and severity of chronic MS lesions follows a periventricular gradient","volume":"28","author":"Klistorner","year":"2022","journal-title":"Multiple Sclerosis J"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2399","article-title":"Association of chronic active multiple sclerosis lesions with disability in vivo","volume":"76","author":"Absinta","year":"2019","journal-title":"JAMA Neurol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14873","article-title":"Characterization of chronic active multiple sclerosis lesions with sodium ( 23 Na) magnetic resonance imaging-preliminary observations","volume":"28","author":"Eisele","year":"2021","journal-title":"Eur J Neurol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012326","article-title":"Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis","volume":"97","author":"Maggi","year":"2021","journal-title":"Neurology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-019-0178-4","article-title":"Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in","volume":"8","author":"Van Schependom","year":"2019","journal-title":"Transl Neurodegener"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.03116\/PDF","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2019","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.11.005","article-title":"Microglia in central nervous system inflammation and multiple sclerosis pathology","volume":"25","author":"Voet","year":"2019","journal-title":"Trends Mol Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx113","article-title":"Loss of \u201chomeostatic\u201d microglia and patterns of their activation in active multiple sclerosis","volume":"140","author":"Zrzavy","year":"2017","journal-title":"Brain"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa158","article-title":"Molecular signature of slowly expanding lesions in progressive multiple sclerosis","volume":"143","author":"J\u00e4ckle","year":"2020","journal-title":"Brain"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the \u201creal MS","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"Cree","year":"2019","journal-title":"Ann Neurol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517709619","article-title":"Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study","volume":"24","author":"Kappos","year":"2018","journal-title":"Mult Scler"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1212\/NXI.0000000000000443","article-title":"Microglial activation, white matter tract damage, and disability in MS","volume":"5","author":"Rissanen","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011700","article-title":"Structural and clinical correlates of a periventricular gradient of neuroinflammation in multiple sclerosis","volume":"96","author":"Poirion","year":"2021","journal-title":"Neurology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001182","article-title":"Innate immune cell\u2013related pathology in the thalamus signals a risk for disability progression in multiple sclerosis","volume":"9","author":"Misin","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2020.1822817","article-title":"Bruton\u2019s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis","volume":"25","author":"Carnero Contentti","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-019-09839-0","article-title":"Inhibition of bruton\u2019s tyrosine kinase modulates microglial phagocytosis: therapeutic implications for alzheimer\u2019s disease","volume":"14","author":"Keaney","year":"2019","journal-title":"J Neuroimmune Pharmacol"},{"key":"B108","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.96.15_supplement.1974","article-title":"Establishing a role for the bruton\u2019s tyrosine kinase inhibitor tolebrutinib in modulating neuroinflammation and disease progression in MS (1974)","volume":"96","author":"Gruber","year":"2021","journal-title":"Neurology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00675-0","article-title":"Emerging therapies to target CNS pathophysiology in multiple sclerosis","volume":"18","author":"Oh","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604681103","article-title":"Glatiramer acetate fights against alzheimer\u2019s disease by inducing dendritic-like microglia expressing insulin-like growth factor 1","volume":"103","author":"Butovsky","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-018-1125-5","article-title":"Dimethyl fumarate attenuates reactive microglia and long-term memory deficits following systemic immune challenge","volume":"15","author":"Paraiso","year":"2018","journal-title":"J Neuroinflamm"},{"key":"B113","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/antiox9080700","article-title":"Exploring the use of dimethyl fumarate as microglia modulator for neurodegenerative diseases treatment","volume":"9","author":"Rosito","year":"2020","journal-title":"Antioxidants"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-215074","article-title":"Dimethyl fumarate is a potential therapeutic option for alzheimer\u2019s disease","volume":"85","author":"Sun","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0088854","article-title":"A systematic review of biomarkers for disease progression in alzheimer\u2019s disease","volume":"9","author":"McGhee","year":"2014","journal-title":"PloS One"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-014-8657-1","article-title":"Body fluid cytokine levels in mild cognitive impairment and alzheimer\u2019s disease: a comparative overview","volume":"50","author":"Brosseron","year":"2014","journal-title":"Mol Neurobiol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1159\/000496920","article-title":"Cerebrospinal fluid biomarkers for the diagnosis of prodromal alzheimer\u2019s disease in amnestic mild cognitive impairment","volume":"9","author":"Park","year":"2019","journal-title":"Dement Geriatr Cognit Dis Extra"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102870","article-title":"A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: a systematic review and meta-analysis","volume":"1","author":"Sun","year":"2021","journal-title":"Multiple Sclerosis Related Disord"},{"key":"B119","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.3390\/ijms21124312","article-title":"Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis","volume":"21","author":"Bross","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1162340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T01:33:57Z","timestamp":1702776837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1162340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":120,"alternative-id":["10.3389\/fimmu.2023.1162340"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1162340","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"article-number":"1162340"}}